Výsledky vyhledávání - "L. Peyrin‐Biroulet"

P664 Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBD

Publikováno v: Journal of Crohn's and Colitis. 17:i794-i797

Background Recruitment rates for phase 2b/3 randomized controlled trials (RCTs) in IBD have substantially dropped over time. Several steps are required prior to successful patient randomization. Initially the physician must propose a trial to a poten

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c64c0b4a6137305b48722054b0293fb2
https://doi.org/10.1093/ecco-jcc/jjac190.0794

Zobrazit plný text záznamu

OP35 Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200 mg among patients with Ulcerative Colitis: Results from the SELECTIONLTE study

Autor: B G Feagan, K Matsuoka, G Rogler, M Faes, A Oortwijn, A de Haas, C Rudolph, L Peyrin-Biroulet

Publikováno v: Journal of Crohn's and Colitis. 17:i47-i50

Background Filgotinib (FIL) is a once-daily, oral, Janus kinase 1 preferential inhibitor approved for the treatment of ulcerative colitis (UC). FIL 200 mg (FIL200) was effective in inducing and maintaining clinical remission vs placebo (PBO) and well

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7671eb56a4cfe20c5da33d4d96b73776
https://doi.org/10.1093/ecco-jcc/jjac190.0035

Zobrazit plný text záznamu

P520 Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programme

Autor: J van der Woude, S Schreiber, L Peyrin-Biroulet, Z Szekanecz, E H Choy, P J Stiers, P Van Hoek, K Van Beneden, A de Haas, C Rudolph, H ten Cate

Publikováno v: Journal of Crohn's and Colitis. 17:i646-i649

Background The once-daily, oral, Janus kinase 1 preferential inhibitor filgotinib (FIL) is approved for the treatment of moderately to severely active rheumatoid arthritis (RA) and ulcerative colitis (UC) in the UK, the EU and Japan.1 To further unde

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::912daa445de5ea4934b459b16d506285
https://doi.org/10.1093/ecco-jcc/jjac190.0650

Zobrazit plný text záznamu

OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results

Autor: B Sands, L Peyrin-Biroulet, S Danese, D T Rubin, S Vermeire, O Laurent, A Luo, D Nguyen, J D Lu, A Wiechowska-Kozlowska, J Leszczyszyn, R Kempinski, J Kierkus, C Ma, T Ritter, B G Feagan, S Targan

Publikováno v: Journal of Crohn's and Colitis. 17:i56-i59

Background Tumor necrosis factor-like cytokine 1A (TL1A) is an upstream regulator of pro-inflammatory cytokines and fibrosis signals. PRA023 is an anti-TL1A monoclonal antibody in development for multiple inflammatory/fibrotic diseases using a precis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6088546255936461055d38ed3c8001d9
https://doi.org/10.1093/ecco-jcc/jjac190.0040

Zobrazit plný text záznamu

P696 Design and rationale for the multicentre, randomised, controlled VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis

Autor: V Jairath, G Zou, G Radulescu, J Sigler, S C Mcfarlane, S Adsul, M Freire, L Peyrin-Biroulet, J F Colombel, G W Moran, S Sebastian, S Travis, S Vermeire, W J Sandborn, G R D’Haens, B G Feagan

Publikováno v: Journal of Crohn's and Colitis. 17:i826-i829

Background Symptoms, endoscopy, histology, and biomarkers are used to evaluate disease activity and response to therapy in ulcerative colitis (UC). Histologic disease activity may persist in ~25% of patients with normal-appearing endoscopic mucosa, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e0d2f7adef5008ee0566e2981e1ba79
https://doi.org/10.1093/ecco-jcc/jjac190.0826

Zobrazit plný text záznamu

P379 Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn’s disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies

Autor: S Vermeire, S Danese, B L Cohen, F Magro, Y Chen, C Ha, E Dubcenco, A P Lacerda, E Marced, J Oomen, A Garrison, L Peyrin-Biroulet

Publikováno v: Journal of Crohn's and Colitis. 17:i510-i513

Background Improvement in clinical outcomes and normalisation of objective markers of inflammation, high-sensitivity C-reactive protein (hs-CRP) and faecal calprotectin (FCP), are considered treatment targets per STRIDE-II guidelines.1 We evaluated t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d11415b6dd2afd6099e3e4781104ad9
https://doi.org/10.1093/ecco-jcc/jjac190.0509

Zobrazit plný text záznamu

P185 Global perception of normal life by healthcare professionals and IBD patients: mind the gap

Autor: J Van Oostrom, S Anjie, M Braad, J Horrigan, N Karimi, B Adi, G Ganesh, S K Yang, J Lasa, C Broër, A de Kruif, P Olivera Sendra, B D Ye, R Banerjee, S Connor, C Siegel, L Peyrin-Biroulet, K Gecse, G D'Haens

Publikováno v: Journal of Crohn's and Colitis. 17:i337-i339

Background For patients living with inflammatory bowel diseases (IBD), the ultimate treatment goal is “normal life”. However, no patient-reported outcome measurement (PROM) exists to measure the level of life normality in IBD. We previously asked

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e013f0f8b9e9b3b0255e6c3796416c79
https://doi.org/10.1093/ecco-jcc/jjac190.0315

Zobrazit plný text záznamu

OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics

Autor: L Peyrin-Biroulet, G Parkes, C Rodríguez, J Siffledeen, J Wright, E Broide, S Ford, A P Lacerda, J Oomen, A Garrison, S Berg, D T Rubin

Publikováno v: Journal of Crohn's and Colitis. 17:i20-i22

Background Biologic therapies are used to treat moderate-to-severe Crohn’s Disease (CD), but many patients eventually lose response to them. With new potential therapies for CD, understanding their efficacy after patients undergo biologic treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b1528d1677ee5a570a82a82b109e8d14
https://doi.org/10.1093/ecco-jcc/jjac190.0016

Zobrazit plný text záznamu

P375 Izencitinib induction treatment in patients with moderately-to-severely-active Crohn’s Disease: A phase 2 double-blind, randomized, placebo-controlled study

Autor: S Schreiber, W Reinisch, D Nguyen, T Guerin, J Kierkus, P Rozpondek, D Bourdet, B Abhyankar, L Peyrin-Biroulet

Publikováno v: Journal of Crohn's and Colitis. 17:i505-i507

Background The unmet need in Crohn’s disease (CD) exists for new medications with an optimized risk-benefit ratio with avoidance of systemic side effects. This Phase 2 study evaluated the efficacy and safety of the oral, once-daily, gut-selective p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::96931872b93518512f3b9010ec9178de
https://doi.org/10.1093/ecco-jcc/jjac190.0505

Zobrazit plný text záznamu

P548 Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn’s disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies

Autor: R Atreya, P Irving, M Fujiya, J F Colombel, S Danese, L Peyrin-Biroulet, T Bessissow, R Panaccione, G D’Haens, S van Haaren, E Neimark, J Zambrano, Y Zhang, K Kligys, M Ferrante

Publikováno v: Journal of Crohn's and Colitis. 17:i675-i677

Background In the risankizumab (RZB) phase 3 clinical programme, Crohn’s disease (CD) patients who responded to RZB intravenous (IV) induction were re-randomised to RZB or placebo (PBO) (withdrawal PBO subcutaneous [SC] in maintenance (FORTIFY), wh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::84914133fddf23b45f465ef1cd068b55
https://doi.org/10.1093/ecco-jcc/jjac190.0678

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání